Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6,433 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Discovery of novel 1,2,4-triazole phenylalanine derivatives targeting an unexplored region within the interprotomer pocket of the HIV capsid protein.
Jiang X, Sharma PP, Rathi B, Ji X, Hu L, Gao Z, Kang D, Wang Z, Xie M, Xu S, Zhang X, De Clercq E, Cocklin S, Pannecouque C, Dick A, Liu X, Zhan P. Jiang X, et al. Among authors: xie m. J Med Virol. 2022 Dec;94(12):5975-5986. doi: 10.1002/jmv.28064. Epub 2022 Aug 18. J Med Virol. 2022. PMID: 35949003 Free PMC article.
Structure-Based Optimization of 2,4,5-Trisubstituted Pyrimidines as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: Exploiting the Tolerant Regions of the Non-Nucleoside Reverse Transcriptase Inhibitors' Binding Pocket.
Zhao F, Zhang H, Xie M, Meng B, Liu N, Dun C, Qin Y, Gao S, De Clercq E, Pannecouque C, Tang YJ, Zhan P, Liu X, Kang D. Zhao F, et al. Among authors: xie m. J Med Chem. 2023 Feb 9;66(3):2102-2115. doi: 10.1021/acs.jmedchem.2c01875. Epub 2023 Jan 26. J Med Chem. 2023. PMID: 36700940
Escaping from Flatland: Multiparameter Optimization Leads to the Discovery of Novel Tetrahydropyrido[4,3-d]pyrimidine Derivatives as Human Immunodeficiency Virus-1 Non-nucleoside Reverse Transcriptase Inhibitors with Superior Antiviral Activities against Non-nucleoside Reverse Transcriptase Inhibitor-Resistant Variants and Favorable Drug-like Profiles.
Wang Z, Sharma PP, Rathi B, Xie M, De Clercq E, Pannecouque C, Kang D, Zhan P, Liu X. Wang Z, et al. Among authors: xie m. J Med Chem. 2023 Jul 13;66(13):8643-8665. doi: 10.1021/acs.jmedchem.3c00275. Epub 2023 May 31. J Med Chem. 2023. PMID: 37255025
Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study.
Xie M, Vuko M, Rodriguez-Canales J, Zimmermann J, Schick M, O'Brien C, Paz-Ares L, Goldman JW, Garassino MC, Gay CM, Heymach JV, Jiang H, Barrett JC, Stewart RA, Lai Z, Byers LA, Rudin CM, Shrestha Y. Xie M, et al. Mol Cancer. 2024 May 30;23(1):115. doi: 10.1186/s12943-024-02014-x. Mol Cancer. 2024. PMID: 38811992 Clinical Trial.
6,433 results